Received Jan 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | LA |
the daughter had swelling and a bump in the vaccination site/ bump is the size of a half of a dollar, and that they can see the bump through the skin; Pain in the injection site; This non-serious case was reported by a consumer via sales rep and described the occurrence of injection site swelling in a female patient who received Men B NVS (Bexsero) for prophylaxis. On 02-JAN-2026, the patient received the 2nd dose of Bexsero (left deltoid). In JAN-2026, less than a week after receiving Bexsero, the patient experienced injection site swelling (Verbatim: the daughter had swelling and a bump in the vaccination site/ bump is the size of a half of a dollar, and that they can see the bump through the skin) and injection site pain (Verbatim: Pain in the injection site). The outcome of the injection site swelling and injection site pain were unknown. It was unknown if the reporter considered the injection site swelling and injection site pain to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the injection site swelling and injection site pain to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-JAN-2026 The batch number was not provided upon follow- up with the reporter.